← Back to all trials
Not Yet Recruiting
NCT05749510
Prediction of Radiation-induced Late Intestinal Injury
Conditions: Radiation-induced Intestinal Injury
Sex: All
Ages: 18 Years – 75 Years
Enrollment: 200
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Summary
Our team has constructed a prediction model based on the phase separation level of DNA repair factors (MRNIP、NONO、NOP53) to predict radiation-induced late intestinal injury (RLII) and verified the predictive efficacy of the system in retrospective studies.
This clinical study intends to further prospectively verify the accuracy of this prediction model in rectal cancer patients.
In this study, we plan to enroll 200 patients diagnosed with locally advanced rectal cancer by pathology and MRI, who undergo neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME).
We will follow up the occurrence and progression of radiation-induced intestinal injury within 1 year after TME.
Phase separation level of DNA repair factors will be detected in pathological tissue after TME and applied to the prediction model to predict RLII.
Based on the clinical diagnosis of RLII, the area under curve (AUC), accuracy, precision, specificity, and sensitivity of this prediction model in predicting RLII will be evaluated.
The main outcome hypothesis is that the AUC of RLII predicted by the prediction model based on the phase separation level of DNA repair factors is more than 0.8.
Eligibility Criteria
Inclusion Criteria:Written informed consent.
18-75 years of age.
ECOG score for performance status is 0-2.
Locally advanced rectal adenocarcinoma (T3-4/N+M0) with pathological and MRI diagnosis.
Patient will undergo NCRT and TME therapies.Exclusion Criteria:Patients with other active malignant tumors.
Patients who have received pelvic radiotherapy or immunotherapy.
Pathological tissue cannot be obtained after TME.
Patients with toxicity (CTCAE Grade ≥ 2) caused by previous treatment that has not subsided.
Pregnant or lactating women.
Source: ClinicalTrials.gov (NCT05749510). StuddyBuddy aggregates publicly available trial information.